Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 10NIH 7OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Thoracic 1Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Lymphoma × Nivolumab × Clear all
NCT02681302 2026-04-03

CPIT001

Hackensack Meridian Health

Phase 1/2 Terminated
46 enrolled 13 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04022980 2025-12-30

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

Wake Forest University Health Sciences

Phase 1 Completed
14 enrolled
Lymphoid

Lymphoma, Neurologic Manifestations

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Rutgers, The State University of New Jersey

Phase 1 Completed
14 enrolled 13 charts
DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03580408 2022-08-19

Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Completed
64 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT03588936 2021-10-11

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Medical College of Wisconsin

Phase 1 Terminated
2 enrolled
LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡